


# CLAIMS

What is claimed is:

1. A method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B (NF- $\kappa$ B) transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof.

2. The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound of Formula I



or a pharmaceutically acceptable salt thereof, wherein:

X and Y are selected from oxygen, sulfur and  $(\text{CR}'\text{R}'')_n$ , wherein n is an integer of from 1 to 4 and R' and R'' are each independently hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, phenyl optionally substituted or R' and R'' together form a spirocycloalkyl or a carbonyl;

with the proviso at least one of X and Y is  $-(\text{CR}'\text{R}'')_n$ - and with the further proviso when X and Y are both  $(\text{CR}'\text{R}'')_n$  and R' and R'' are hydrogen and n is one, R<sub>1</sub> and R<sub>2</sub> are aryl;

R is hydrogen, a straight or branched alkyl of from 1 to 8 carbon atoms or benzyl;

R<sub>1</sub> and R<sub>2</sub> are each independently selected from:

- (a) phenyl or phenoxy each of which is unsubstituted or is substituted with from 1 to 5 substituents selected from:
  - phenyl,
  - an alkyl group having from 1 to 6 carbon atoms and which is straight or branched,

an alkoxy group having from 1 to 6 carbon atoms and which is straight or branched;

phenoxy,

hydroxy,

5

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

10

-COOH,

-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and is straight or branched, and

-(CH<sub>2</sub>)<sub>p</sub>NR<sub>3</sub>R<sub>4</sub>, wherein p is zero or one, and each of R<sub>3</sub> and R<sub>4</sub> is selected from hydrogen or a straight or branched alkyl group having 1 to 4 carbon atoms;

15

(b) 1- or 2-naphthyl unsubstituted or substituted with from 1 to 3 substituents selected from:

phenyl,

an alkyl group having from 1 to 6 carbon atoms and which is straight or branched,

20

an alkoxy group having from 1 to 6 carbon atoms and which is straight or branched;

hydroxy,

phenoxy,

25

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

30

-COOH,

-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and is straight or branched, and

$-(CH_2)_pNR_3R_4$ , wherein p,  $R_3$  and  $R_4$  have the meanings defined above;


- (c) arylalkyl;
- (d) a straight or branched alkyl chain having from 1 to 20 carbon atoms and which is saturated or contains from 1 to 3 double bonds; and
- (e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms;

5

with the provisos:—

10

- (i) where X is  $(CH_2)_n$ , Y is oxygen, and  $R_1$  is a substituted phenyl, then  $R_2$  is a substituted phenyl;
- (ii) where Y is oxygen, X is  $(CH_2)_n$ ,  $R_2$  is phenyl or naphthyl, then  $R^1$  is not a straight or branched alkyl chain; and
- (iii) the following compounds are excluded:

X	Y	R	$R_1$	$R_2$
$CH_2$	O	H	$(CH_2)CH_3$	Ph
$CH_2$	O	H	$CH_3$	Ph
$CH_2$	O	H		i-Pr

15

with the further proviso that compounds selected from the group consisting of:

Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl]propyl]-  
2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [fluoro[2,4,6-tris(1-methylethyl)phenyl]acetyl]-  
2,6-bis(1-methylethyl)phenyl ester, and

20

Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-  
2,6-bis(phenyl)phenyl ester

are excluded.

3. The method according to Claim 2, wherein the sulfonylaminocarbonyl derivative is a compound of Formula I, or a pharmaceutically acceptable salt thereof, selected from:

- 5 (1,2,3,4-Tetrahydro-naphthalene-2-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;  
[Bis-(4-chloro-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;  
(Bromo-phenyl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;  
10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxy-2,6-diisopropyl-phenyl ester;  
Methyl-[(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-nitro-phenyl ester;  
15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-fluoro-2,6-diisopropyl-phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dimethoxy-phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-  
20 diisopropyl-phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,4,6-trimethoxy-phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-tert-butyl-2,6-diisopropyl-phenyl ester;  
25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetyl-2-isopropyl-phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methoxy-phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dichloro-  
30 phenyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid dodecyl ester;  
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-bromo-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methyl-phenyl ester;

[1-(4-Dimethylamino-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

5 [1-(4-Nitro-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

3,5-Diisopropyl-4- {[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-benzoic acid methyl ester;

10 Sulfamic acid (phenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;

15 Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,4,6-tris(1-methylethyl)phenyl ester;

Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,4,6-tris(1-methylethyl)phenyl ester;

Sulfamic acid[adamantaneacetyl]-2,6-bis(1-methylethyl)phenyl ester;

20 Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt;

Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt;

25 Sulfamic acid (decanoyl)-2,6-bis-(1-methylethyl)phenyl ester;

Sulfamic acid (dodecanoyl)-2,6-bis-(1-methylethyl)phenyl ester;  
2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]-methyl]sulfonyl]benzeneacetamide;

2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]-methyl]sulfonyl]benzeneacetamide-sodium salt;

30 2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]-methyl]sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]-methyl]sulfonyl]carbamate-sodium salt;

Sulfamic acid (1-oxo-3,3-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

5 Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester sodium salt;

Sulfamic acid trans-[(2-phenylcyclopropyl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester;

10 Sulfamic acid [2,5-dimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,4,6-trimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,4,6-trimethylphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

15 Sulfamic acid [2-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [3-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

20 Sulfamic acid [2-methoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (oxophenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2-trifluoromethylphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

25 Sulfamic acid (1-oxo-2-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (cyclopentylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

30 Sulfamic acid (cyclohexylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (diphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (triphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [(1-phenylcyclopentyl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-2,6-bis(1-methylethyl)phenyl ester;

5 Sulfamic acid (1-oxo-2-phenylbutyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (cyclohexylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

10 Sulfamic acid (1-oxo-2,2-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [(9H-fluoren-9-yl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (1-oxo-3-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

15 Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl]-2-propenyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [(acetyloxy)[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;

20 Sulfamic acid [hydroxy[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-2,6-bis(1-methylethyl)phenyl ester sodium salt;


Sulfamic acid [[2,4,6-tris(1-methylethyl)phenoxy]acetyl]-2,6-bis(1-methylethyl)phenyl ester; and

25 Sulfamic acid [[2,6-bis(1-methylethyl)phenoxy]acetyl]-2,6-bis(1-methylethyl)phenyl ester.

4. The method according to Claim 2, wherein the sulfonylaminocarbonyl derivative is sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester, or a pharmaceutically acceptable salt thereof.

30

5. The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound of Formula II



II

or a pharmaceutically acceptable salt thereof, wherein:



- 5  $R^1$  is hydrogen, alkyl, or alkoxy;  
 $R^2$  to  $R^5$  are alkyl, alkoxy, or unsubstituted or substituted phenyl; and  
 $R^6$  is -CN,  
 10  $-(CH_2)_{0-1}-NR^7R^8$ ,  
 $-O-(CH_2)_{1-10}-Z$ , wherein Z is  $-NR^9R^{10}$ ,  $OR^1$ , or  $CO_2R^1$ ,  
 $-OC(=O)R^{11}$ ,  
 $-SR^{11}$ ,  
 $-SCN$ ,  
 $-S(CH_2)_{1-10}Z$ ,  
 $-S(O)_{1-2}R^{12}$ , wherein  $R^{12}$  is hydroxy, alkoxy, alkyl,  $(CH_2)_{1-10}Z$   
 15 or  $NR^7R^8$ ,  
 $-C(=O)XR^{11}$ , or  
 $-CH_2-R^{13}$ , wherein  $R^{13}$  is  $(CH_2)_{0-5}-Y-(CH_2)_{0-5}Z$ , or alkyl of  
 from 1 to 20 carbons with from 1-3 double bonds, which  
 alkyl is optionally substituted by one or more moieties  
 20 selected from -CN,  $NO_2$ , halogen,  $OR^1$ ,  $NR^9R^{10}$ , and  
 $CO_2R^1$ ;

wherein  $R^7$  and  $R^8$  are each independently selected from:



- hydrogen, at least one of  $R^7$  and  $R^8$  is other than hydrogen,  
 $-(CH_2)_{1-10}Z$ , wherein Z is as defined above and  $R^9$  and  $R^{10}$  are  
 25 each independently selected from hydrogen, alkyl, and  
 unsubstituted or substituted phenyl, or



R<sup>9</sup> and R<sup>10</sup> are taken together with the nitrogen to which they are attached to form a ring selected from:



5



are each independently selected from hydrogen, alkyl, and unsubstituted or substituted phenyl;

10

-C(=Q)XR<sup>11</sup>, wherein X is a bond or NH wherein Q is O or S, R<sup>11</sup> is hydrogen, alkyl, unsubstituted or substituted phenyl,

-(CH<sub>2</sub>)<sub>0-5</sub>-Y-(CH<sub>2</sub>)<sub>0-5</sub>Z, wherein Z is as defined above and Y is phenyl or a bond;

-C(=O)-CR<sup>17</sup>R<sup>18</sup>Z;



15



-C(=O)NHCR<sup>17</sup>R<sup>18</sup>Z, wherein R<sup>17</sup> and R<sup>18</sup> are each independently hydrogen, alkyl, phenyl, substituted phenyl, or the side chain of a naturally occurring amino acid;

-S(O)<sub>1-2</sub>R<sup>19</sup>, wherein R<sup>19</sup> is alkyl, unsubstituted or substituted phenyl, naphthyl, or a heteroaromatic ring, or NR<sup>9</sup>R<sup>10</sup> or

20

R<sup>7</sup> and R<sup>8</sup> are taken together with the nitrogen to which they are attached to form a ring selected from:





5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-formyl-

2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-  
2,6-diisopropyl-phenyl ester;

10

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-  
4-(4-methyl-piperazin-1-ylmethyl)-phenyl ester, dihydrochloride;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[bis-(2-hydroxy-  
ethyl)-amino]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-  
4-(3-phenyl-thioureido)-phenyl ester; and

15

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-  
4-sulfamoyl-phenyl ester

are excluded.

20

6. The method according to Claim 5, wherein the sulfonylaminocarbonyl derivative is a compound of Formula II, or a pharmaceutically acceptable salt thereof, selected from:

6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-  
acetyl]sulfamoyloxy)-phenyl)-hexanoic acid ethyl ester;

3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-  
acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid ethyl ester;

25

{[4-(1-Hydroxy-1-methyl-ethyl)-2,6-diisopropyl-phenyl]-acetyl}-  
sulfamic acid 2,6-diisopropyl-phenyl ester;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-  
amino-4-methyl-pentanoylamino)-2,6-diisopropyl-phenyl ester; compound  
with trifluoro-acetic acid;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-tert-butyl-ureido)-2,6-diisopropyl-phenyl ester;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid;

5

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl ester;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-hydroxy-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid;

10

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-carbamoyl-butyrylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-methyl-butyrylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid;

15

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(3,5-dichloro-phenyl)-thioureido]-2,6-diisopropyl-phenyl ester;

(S)-[5-tert-Butoxycarbonylamino-5-(3,5-diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenylcarbamoyl]-pentyl]-carbamic acid tert-butyl ester;

20

(S)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2,6-diamino-hexanoylamino)-2,6-diisopropyl-phenyl ester dihydrochloride;

25

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-acetyl-amino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-acetyl-amino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-4-methylsulfanyl-butyrylamino)-2,6-diisopropyl-phenyl ester;

30

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-4-methylsulfanyl-butyrylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate;

5 3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid ethyl ester;

3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid;

10 3-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[2-amino-3-(1H-indol-3-yl)-propionylamino]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-amino-pentanoylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate(1:1)(salt);

(D)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-propionylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate(1:1)(salt);

15 (L)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-propionylamino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-2-methyl-propionylamino)-2,6-diisopropyl-phenyl ester;

20 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt;

25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-cyano-2,6-diisopropyl-phenyl ester;

30 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[(2-amino-acetylamino)-methyl]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(benzylamino-methyl)-2,6-diisopropyl-phenyl ester mono hydrochloride;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-carbamoyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxymethyl-2,6-diisopropyl-phenyl ester;

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetylamino-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-hydroxy-ethylamino)-2,6-diisopropyl-phenyl ester;

10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(2,6-diisopropyl-phenyl)-ureido]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-ureido)-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(thiophene-2-sulfonylamino)-phenyl ester;

15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-dimethylamino-naphthalene-1-sulfonylamino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methanesulfonylamino-phenyl ester;

20 6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-hexanoic acid ethyl ester; and

6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-hexanoic acid.

25 7. The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

(9H-Xanthene-9-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

30 ((E)-2-Methyl-3-phenyl-acryloyl)-sulfamic acid 2,6-diisopropyl-phenyl ester; and

(2-Oxo-2H-chromene-3-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester.

8. The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

5 Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-hydroxyphenyl ester;

Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

10 Carbamic acid, [(didecylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester;

Carbamic acid, [[bis(1-methylethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

15 Carbamic acid, [(dipentylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[[diphenylmethyl)amino]sulfonyl]methyl-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

DL-Tryptophan,  $\alpha$ -methyl-N-[[[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yloxy)carbonyl]amino]sulfonyl]-, methyl ester;

20 Carbamic acid, sulfonylbis-, bis[2,6-bis(1-methylethyl)phenyl] ester;

Carbamic acid, [[[2-(phenylmethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

25 Methyl[[2,6-bis(1-methylethyl)phenyl amino]sulfonyl]carbamate;  
Dodecyl[[[2,6-bis(1-methylethyl)phenyl] amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methoxyphenyl [[(2,2-diphenylethyl)-amino]sulfonyl]carbamate;

30 2,6-Bis(1,1-dimethylethyl)-4-methoxy phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)phenyl-[[[(diphenylmethyl)amino]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)phenyl [[[2,6-bis(1-methylethyl)phenyl]-amino]sulfonyl] carbamate;

2,6-Bis(1,1-dimethylethyl)phenyl [[(2,2-diphenylethyl)amino]-sulfonyl]carbamate;

5                    2,6-Bis(1,1-dimethylethyl)phenyl [[bis(phenylmethyl)amino]-sulfonyl]carbamate;

2,6-bis(1-methylethyl)phenyl[(diphenyl-amino)sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(dibutyl-amino)sulfonyl]carbamate;

10                    2,6-Bis(1-methylethyl)phenyl[[bis(phenyl-methyl)amino]sulfonyl]-carbamate;

2,6-Bis(1-methylethyl)phenyl[(1H-benzimidazol-2-ylamino)-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[[2,2-diphenylethyl)amino]sulfonyl]-carbamate;

15                    2,6-Bis(1-methylethyl)phenyl[[[2,6-bis(1-methylethyl)phenyl]-amino]sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[[bis(phenyl-methyl)amino]sulfonyl]-carbamate;

20                    2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[bis(phenylmethyl)-amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[2,2-diphenylethyl)-amino]sulfonyl]-carbamate;

25                    2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dibutylamino)-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dipentylamino)-sulfonyl]carbamate;

30                    2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[bis(1-methylethyl)amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dihexylamino)-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(hexylamino)-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[methyl(2-phenylethyl)amino]sulfonyl]carbamate;

5 2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[bis-3-(dimethylamino)propyl]amino]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(methyl octyl amino)-sulfonyl]carbamate;

10 2,6-Bis(1,1-dimethylethyl)-4-methyl-[[bis[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dioctylamino)-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]sulfonyl]carbamate, hydrochloride salt;

15 2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]-sulfonyl]carbamate, sodium salt;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dodecylamino)-sulfonyl]carbamate;

20 2,6-Bis(1-methylethyl)phenyl[[bis(1-methylethyl)amino]sulfonyl]-carbamate;

2,6-Bis(1-methylethyl)phenyl[((1-methylethyl)phenylmethyl)-amino]sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(hexyl-amino)sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(dioctyl-amino)sulfonyl]carbamate;

25 2,6-Bis(1-methylethyl)phenyl[[cyclo-hexyl(1-methylethyl)amino]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(methyl-octylamino)sulfonyl]-carbamate;

2,6-Bis(1-methylethyl)phenyl[(dihexyl-amino)sulfonyl]carbamate;

30 Dodecyl[(2,4,6-trimethoxyphenyl)amino]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl ester(4-morpholinylsulfonyl)-carbamic acid;



2,6-Bis(1-methylethyl)phenyl ester(1-piperidinylsulfonyl)carbamic acid;

2,6-Bis(1-methylethyl)phenyl ester(1-pyrrolidinylsulfonyl)-carbamic acid;

5                    2,6-Bis(1-methylethyl)phenyl ester[(2,3-dihydro-1H-indol-1-yl)sulfonyl]carbamic acid;

2,6-Bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate monosodium salt; and

10                    2,6-Bis(1,1-dimethylethyl)phenyl[((diphenylmethyl)amino)-sulfonyl]methyl carbamate.

9.     The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

15                    Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dipropylamino)-sulfonyl]-;

Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-  
[[[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)amino]sulfonyl]-, (4*S*-*cis*)-;

Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-[[[(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)amino]sulfonyl]-, stereoisomer;

20                    N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylethyl)amino]-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(diphenylmethyl)amino]-sulfonyl]urea;

25                    N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diphenylamino)-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dibutylamino)sulfonyl]urea;

N-[[[2,6-bis(1-methylethyl)phenyl]amino]-sulfonyl]-N'-  
(diphenylmethyl)urea;

30                    N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[2,6-bis(1-methylethyl)-phenyl]amino]sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(2,2-diphenylethyl)-amino]sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(9H-fluoren-9-ylamino)-sulfonyl]urea;

5 N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(phenylmethyl)amino]-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-methylethyl)-(phenylmethyl)amino]sulfonyl]urea;

10 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dioctylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(4-phenyl-1-piperidiny]-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dihexylamino)sulfonyl]-urea;

15 N-[[bis[3-(dimethylamino)propyl]amino]-sulfonyl]-N'-[2,6-bis(1-methylethyl)phenyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(hexylamino)sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis-[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]-urea;

20 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diethylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctylamino)sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[cyclohexyl(1-methylethyl)amino]sulfonyl]urea;

25 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dipentylamino)sulfonyl]-urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(2-methylpropyl)amino]-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[ethyl(2-propenyl)amino]-sulfonyl]urea;

30 N-[[bis(3-methylbutyl)amino]sulfonyl]-N'-[2,6-bis(1-methylethyl)-phenyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-  
 [(didecylamino)sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(didodecylamino)-  
 sulfamoyl]urea;

5 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diisopropylamino)-  
 sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dicyclohexylamino)-  
 sulfonyl]urea;

10 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctadecylamino)-  
 sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(di-2-propenylamino)-  
 sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1,1-dimethylethyl](1-  
 methylethyl)amino]sulfonyl]-urea;

15 N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylpropyl)amino]-  
 sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyltetradecylamino)-  
 sulfonyl]urea;

20 N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-pyrrolidinylsulfonyl)urea;  
 N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-piperidinylsulfonyl)urea;  
 N'-[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-N,N-  
 bis(phenylmethyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dibutylamino)sulfonyl]urea,  
 monosodium salt; and

25 N'-[2,6-bis(1-methylethyl)phenyl]-N-methyl-[(dibutyl-  
 amino)sulfonyl]urea.

10. The method according to Claim 1, wherein the sulfonylaminocarbonyl  
 derivative is a compound, or a pharmaceutically acceptable salt thereof,  
 selected from:

30 Sulfamic acid, [[[2,4,6-tris(1-methylethyl)phenyl]amino]-  
 carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid, [[[[1-[4-(dimethylamino)phenyl]cyclopentyl]-methyl]amino]carbonyl], 2,6-bis(1-methylethyl)phenyl ester;

(2,3-Dihydro-indole-1-carbonyl)-sulfamic acid 2,6-diisopropylphenyl ester;

5 Sulfamic acid, [(triphenylmethyl)amino]carbonyl-, 2,6-bis(1-methylethyl)phenyl ester;

Octadecyl [[[2,6-bis(1-methylethyl)phenyl]-amino]carbonyl]-sulfamate;

10 Dodecyl-N-[[[2,6-bis(1-methylethyl)phenyl]-amino]carbonyl]-sulfamate;

Decyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]sulfamate;

(±) 1-Methylheptyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]sulfamate;

15 2,6-Bis(1-methylethyl)phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]sulfamate;

(±) 1-Methylundecyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]sulfamate; and

Dodecyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-sulfamate; sodium salt.

20 11. The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

Carbamic acid, [(dodecyloxy)sulfonyl]-, dodecyl ester;

25 Carbamic acid, [(dodecyloxy)sulfonyl]-,[1,1':3',1''-terphenyl]-2'-yl ester;

Carbamothioic acid, [(dodecyloxy)sulfonyl]-, S-[2,6-bis(1-methylethyl)-phenyl] ester;

Carbamic acid, (phenoxysulfonyl)-, 2,6-bis(1-methylethyl)phenyl ester;

30 Carbamic acid, [(2,6-dimethylphenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

5 Carbamic acid, [(2,6-difluorophenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [(hexadecyloxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

10 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethoxyphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1-methylheptyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)-4-nitrophenyl ester;

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2-ethanediyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2,3-propanetriyl ester;

20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-bromo-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl ester;

25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,3,5,6-tetrakis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-chloro-2,6-bis-(1-methylethyl)phenyl ester;

30 Stigmasta-5,22-dien-3-ol, [[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]-carbamate, (3 $\alpha$ )-;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1dimethylethyl)-4-methylphenyl ester;

Stigmastan-3-ol, [[2,7-bis(1-methylethyl)phenoxy]sulfonyl]-  
carbamate, (3 $\alpha$ )-;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
4-methoxy-2,6-bis(1-methylethyl)phenyl ester;

5 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-  
tris(1-methylethyl)phenyl ester;

Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-, 2,6-  
bis(1-methylethyl)phenyl ester;

10 Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-,  
2,4,6-tris(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-  
tris(1,1-dimethylethyl)phenyl ester;

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]dithio]-2,6-bis(1,1-  
dimethylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-  
bis(1-methylethyl)phenyl ester;

20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
4-[(dimethylamino)methyl]-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
4-hydroxy-2,6-bis(1-methylethyl)phenyl ester;

25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
cyclohexyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
3,3',5,5'-tetrakis(1-methylethyl)[1,1'-biphenyl]-4,4'-diyl ester;

Carbamic acid, [[4-hydroxy-2,6-bis(1-methylethyl)phenoxy]-  
sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

30 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl ester;

- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2-(1,1-dimethylethyl)-6-methylphenyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 5-methyl-2-(1-methylethyl)cyclohexyl ester;
- 5 Carbamothioic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, *S*-[2,6-bis(1-methylethyl)phenyl] ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2,6-diethylphenyl)methyl ester;
- 
- 10 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*S*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-(1,1-dimethylethyl)-2,6-bis(1-methylethyl)phenyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluorophenyl ester;
- 15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-difluorophenyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, pentafluorophenyl ester;
- 20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-difluorophenyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*R*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,3,5,6-tetramethylphenyl ester;
- 25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 3-pyridinyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethylphenyl ester;
- 30 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-acetyl-2,6-bis(1-methylethyl)phenyl ester;
- Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,6-bis(1-methylethyl)phenyl ester;

2,6-Bis(1-methylethyl)phenyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl(phenoxy-sulfonyl)-carbamate;

5                    2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(hexyloxy)-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dodecyloxy)-sulfonyl]carbamate;

10                    Dodecyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]carbamate;  
Methyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]carbamate;  
2,6-Bis(1-methylethyl)phenyl[(hexyloxy)-sulfonyl]carbamate;  
2,6-Bis(1-methylethyl)phenyl[(dodecyloxy)-sulfonyl]carbamate;  
and

15                    2,6-Bis(1,1-dimethylethyl)phenyl[[2,6-bis(1-methylethyl)-phenoxy]sulfonyl]carbamate.

12. The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

20                    N-[2,6-bis(1-methylethyl)phenyl]-N'-[(6-ethoxy-2-benzothiazolyl)-sulfonyl]-urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-octadecylsulfonyl)urea;

N-[2,4,6-trimethoxyphenyl]-N'-(2-octadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tetradecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(dodecylsulfonyl)urea;

25                    N-[2,6-bis(1-methylethyl)phenyl]-N'-(hexadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-methyl-N'-

(dodecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tridecylsulfonyl)urea;

N-[2,4,6-trimethoxyphenyl]-N'-(hexadecylsulfonyl)urea;

30                    N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-methyl-2-pentadecylsulfonyl)urea;



N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-tetradecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(dodecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-nonylsulfonyl)urea; and

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-decylsulfonyl)urea.

5

10

15

20

25

13. A method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is rheumatoid arthritis, osteoarthritis, an autoimmune disease, psoriasis, asthma, a cardiovascular disease, an acute coronary syndrome, congestive heart failure, Alzheimer's disease, multiple sclerosis, cancer, type 2 diabetes, metabolic syndrome X, or inflammatory bowel disease.

14. The method according to Claim 13, wherein the disease or disorder being treated is selected from: systemic lupus erythematosus, Grave's disease, myasthenia gravis, insulin resistance, autoimmune hemolytic anemia, scleroderma with anticollagen antibodies, pernicious anemia, and diabetes mellitus.

15. The method according to Claim 13, wherein the disease or disorder being treated is rheumatoid arthritis.

16. The method according to Claim 13, wherein the disease or disorder being treated is osteoarthritis.

17. The method according to Claim 13, wherein the disease or disorder being treated is insulin resistance.

18. The method according to Claim 13, wherein the disease or disorder being treated is asthma.

19. The method according to Claim 13, wherein the disease or disorder being treated is atherosclerosis.
20. The method according to Claim 13, wherein the disease or disorder being treated is myocardial infarction.
- 5 21. The method according to Claim 13, wherein the disease or disorder being treated is unstable angina.
- 
22. The method according to Claim 13, wherein the disease or disorder being treated is congestive heart failure.
23. The method according to Claim 13, wherein the disease or disorder being treated is Alzheimer's disease.
- 10 24. The method according to Claim 13, wherein the disease or disorder being treated is cancer.
25. The method according to Claim 13, wherein the disease or disorder being treated is inflammatory bowel disease.
- 15 26. The method according to Claim 13, wherein the disease or disorder being treated is multiple sclerosis.
27. The method according to Claim 13, wherein the disease or disorder being treated is psoriasis.
28. The method according to Claim 13, wherein the disease or disorder being treated is type 2 diabetes.
- 20 29. The method according to Claim 13, wherein the disease or disorder being treated is metabolic syndrome X.

30. ✓ A method of inhibiting NF- $\kappa$ B transcription factors in an animal, comprising administering to the animal a NF- $\kappa$ B inhibiting amount of a sulfonylaminocarbonyl derivative, or a pharmaceutical acceptable salt thereof.